{Reference Type}: Journal Article
{Title}: PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review.
{Author}: Wang C;Zhang Y;Yu W;Xu J;Xing D;
{Journal}: Int J Biol Macromol
{Volume}: 261
{Issue}: 0
{Year}: 2024 Mar 30
{Factor}: 8.025
{DOI}: 10.1016/j.ijbiomac.2024.129864
{Abstract}: Proteolysis targeting chimera (PROTAC) technology is a promising new mode of targeted protein degradation with significant transformative implications for the clinical treatment of different diseases. Nevertheless, while this technology offers numerous advantages, on-target off-tumour toxicity in healthy cells remains a major challenge for clinical application in cancer therapy. Strategies are presently being explored to optimize degradation activity with cellular selectivity to minimize undesirable side effects. PROTAC-antibody conjugates and PROTAC-aptamer conjugates are unique innovations that combine PROTACs and biomacromolecules. These novel PROTAC-biomacromolecule conjugates (PBCs) can enhance the targetability of PROTACs and reduce their off-target side-effects. The combination of potent PROTACs and highly safe biomacromolecules will pioneer an emerging trend in targeted protein degradation. In our review, we have summarized recent advances in PBCs, discussed current challenges, and outlooked opportunities for future research in the field.